CL2008003092A1 - Producto de dispersion solida que comprende a una agente activo derivado de n-aril urea, un agente formador de matriz seleccionado entre ciclodextrinas, polimeros, lipidos y un tensioactivo no ionico; proceso de preparacion de dicho producto de dispersion; y forma dosificacion farmaceutica que lo comprende . - Google Patents

Producto de dispersion solida que comprende a una agente activo derivado de n-aril urea, un agente formador de matriz seleccionado entre ciclodextrinas, polimeros, lipidos y un tensioactivo no ionico; proceso de preparacion de dicho producto de dispersion; y forma dosificacion farmaceutica que lo comprende .

Info

Publication number
CL2008003092A1
CL2008003092A1 CL2008003092A CL2008003092A CL2008003092A1 CL 2008003092 A1 CL2008003092 A1 CL 2008003092A1 CL 2008003092 A CL2008003092 A CL 2008003092A CL 2008003092 A CL2008003092 A CL 2008003092A CL 2008003092 A1 CL2008003092 A1 CL 2008003092A1
Authority
CL
Chile
Prior art keywords
dispersion product
cyclodextrins
lipids
polymers
matrix
Prior art date
Application number
CL2008003092A
Other languages
English (en)
Inventor
Schroeder Rudolf
Heitermann Tanjia
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of CL2008003092A1 publication Critical patent/CL2008003092A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Producto de dispersión sólida que comprende a compuestos derivados de n-aril urea; proceso de preparación de dicho producto de dispersión sólida.
CL2008003092A 2007-10-19 2008-10-17 Producto de dispersion solida que comprende a una agente activo derivado de n-aril urea, un agente formador de matriz seleccionado entre ciclodextrinas, polimeros, lipidos y un tensioactivo no ionico; proceso de preparacion de dicho producto de dispersion; y forma dosificacion farmaceutica que lo comprende . CL2008003092A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99961307P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
CL2008003092A1 true CL2008003092A1 (es) 2009-11-27

Family

ID=40089072

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003092A CL2008003092A1 (es) 2007-10-19 2008-10-17 Producto de dispersion solida que comprende a una agente activo derivado de n-aril urea, un agente formador de matriz seleccionado entre ciclodextrinas, polimeros, lipidos y un tensioactivo no ionico; proceso de preparacion de dicho producto de dispersion; y forma dosificacion farmaceutica que lo comprende .

Country Status (23)

Country Link
US (1) US20090143423A1 (es)
EP (1) EP2197426A2 (es)
JP (1) JP2011500647A (es)
KR (1) KR20100090689A (es)
CN (1) CN101827585A (es)
AR (1) AR068916A1 (es)
AU (1) AU2008313620A1 (es)
BR (1) BRPI0818339A2 (es)
CA (1) CA2699335A1 (es)
CL (1) CL2008003092A1 (es)
CO (1) CO6270303A2 (es)
CR (1) CR11441A (es)
DO (1) DOP2010000114A (es)
EC (1) ECSP10010184A (es)
GT (1) GT201000095A (es)
MX (1) MX2010004292A (es)
PE (1) PE20091041A1 (es)
RU (1) RU2010119924A (es)
TW (1) TW200922549A (es)
UA (1) UA100866C2 (es)
UY (1) UY31406A1 (es)
WO (1) WO2009050289A2 (es)
ZA (1) ZA201002130B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102186836A (zh) * 2008-10-17 2011-09-14 雅培制药有限公司 Trpv1拮抗剂
US8609692B2 (en) * 2008-10-17 2013-12-17 Abbvie Inc. TRPV1 antagonists
US20100210682A1 (en) * 2009-02-19 2010-08-19 Abbott Laboratories Repeated Dosing of TRPV1 Antagonists
CN102573755A (zh) * 2009-09-18 2012-07-11 巴斯夫欧洲公司 制备具有低水溶性的物质的制剂的方法
CN103260609B (zh) * 2010-12-23 2017-08-11 雅培股份有限两合公司 基于固体分散体的固体延缓制剂
WO2012096859A2 (en) * 2011-01-10 2012-07-19 Celgene Corporation Oral dosage forms of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl]-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amide
HK1201186A1 (en) * 2011-12-29 2015-08-28 Abbvie Inc. Solid compositions comprising an hcv inhibitor
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
PT2950786T (pt) 2013-01-31 2020-03-03 Gilead Pharmasset Llc Formulação de combinação de dois compostos antivirais
CA2903831A1 (en) 2013-03-15 2014-09-25 Boehringer Ingelheim International Gmbh Solid oral dosage formulation of hcv inhibitor in the amorphous state
EP3016641B1 (de) 2013-07-03 2018-09-05 LTS Lohmann Therapie-Systeme AG Transdermales therapeutisches system mit elektronischem bauteil
EA201690473A1 (ru) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Комбинированный состав двух противовирусных соединений
EP3145502B1 (en) 2014-05-20 2022-07-06 LTS Lohmann Therapie-Systeme AG Transdermal delivery system containing rotigotine
US11752110B2 (en) 2014-05-20 2023-09-12 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
WO2015177209A1 (en) 2014-05-20 2015-11-26 Lts Lohmann Therapie-Systeme Ag Method for adjusting the release of active agent in a transdermal delivery system
ES3063790T3 (en) 2015-06-09 2026-04-20 Lonza Sales Ag Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
CA3039767C (en) * 2015-12-22 2023-11-14 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treatment, amelioration, and prevention of anesthesia-induced hypothermia
WO2020092100A1 (en) * 2018-10-30 2020-05-07 Peloton Therapeutics, Inc. Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof
CN118812481A (zh) 2019-08-23 2024-10-22 持田制药株式会社 杂环亚基乙酰胺衍生物的制造方法
WO2021039023A1 (ja) 2019-08-23 2021-03-04 持田製薬株式会社 ヘテロシクリデンアセトアミド誘導体の製造方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362878A (en) * 1991-03-21 1994-11-08 Pfizer Inc. Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)
WO1993024458A1 (en) * 1992-05-28 1993-12-09 Pfizer Inc. New n-aryl and n-heteroarylurea derivatives as inhibitors of acyl coenzyme a:cholesterol acyl transferase (acat)
CN1273526A (zh) * 1998-07-14 2000-11-15 Em工业股份有限公司 微分散给药系统
US7015233B2 (en) * 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
KR20120039763A (ko) * 2004-06-08 2012-04-25 버텍스 파마슈티칼스 인코포레이티드 약학 조성물
WO2006026501A1 (en) * 2004-08-27 2006-03-09 Bayer Pharmaceuticals Corporation New pharmaceutical compositions for the treatment of cancer
JP2008536929A (ja) * 2005-04-18 2008-09-11 ルビコン・リサーチ・ピーヴィーティー・エルティーディー 生体強化組成物
KR100715355B1 (ko) * 2005-09-30 2007-05-07 주식회사유한양행 프란루카스트를 함유하는 분무-건조 과립 및 그의 제조방법
WO2007050574A1 (en) * 2005-10-25 2007-05-03 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
WO2007066189A2 (en) * 2005-12-09 2007-06-14 Pfizer Products Inc. Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea
US7745448B2 (en) * 2005-12-28 2010-06-29 Abbott Laboratories Inc. Crystalline N-(4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl)-N′-(2-fluoro-5-(trifluoromethyl)phenyl)urea ethanolate
JP5773560B2 (ja) * 2006-02-09 2015-09-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｃｅｔｐ阻害剤のポリマー製剤

Also Published As

Publication number Publication date
CO6270303A2 (es) 2011-04-20
ECSP10010184A (es) 2010-06-29
UA100866C2 (ru) 2013-02-11
DOP2010000114A (es) 2010-05-15
CR11441A (es) 2010-10-25
JP2011500647A (ja) 2011-01-06
US20090143423A1 (en) 2009-06-04
EP2197426A2 (en) 2010-06-23
BRPI0818339A2 (pt) 2015-04-22
AR068916A1 (es) 2009-12-16
PE20091041A1 (es) 2009-08-22
RU2010119924A (ru) 2011-11-27
KR20100090689A (ko) 2010-08-16
CA2699335A1 (en) 2009-04-23
CN101827585A (zh) 2010-09-08
AU2008313620A1 (en) 2009-04-23
MX2010004292A (es) 2010-08-02
WO2009050289A3 (en) 2010-03-25
GT201000095A (es) 2012-04-03
UY31406A1 (es) 2009-05-29
WO2009050289A2 (en) 2009-04-23
TW200922549A (en) 2009-06-01
ZA201002130B (en) 2011-11-30

Similar Documents

Publication Publication Date Title
CL2008003092A1 (es) Producto de dispersion solida que comprende a una agente activo derivado de n-aril urea, un agente formador de matriz seleccionado entre ciclodextrinas, polimeros, lipidos y un tensioactivo no ionico; proceso de preparacion de dicho producto de dispersion; y forma dosificacion farmaceutica que lo comprende .
MX2019008762A (es) Composiciones en la forma de estructuras solidas solubles.
MX2009010907A (es) Formulacion del agente activo cargado en nanoparticulas de plga activadas para nano-terapeuticos direccionados para el cancer.
CL2013001586A1 (es) Composicion microgranular de rapida dispersion que comprende al menos un alcohol de azucar, un sacarido, o una mezcla de estos, al menos un super disgregante y al menos un aditivo multifuncion; comprimido de desintegracion oral que comprende la composicion microgranular y al menos un principio activo; y metodos de fabricacion.
CL2015000893A1 (es) Formulación de una forma farmacéutica sólida de desintegración rápida que comprende carbonato de calcio funcionalizado, un ingrediente activo y por lo menos un desintegrante; y método para su fabricación.
CR20110110A (es) Composicion farmaceutica
WO2010015567A3 (en) Controlled release formulations using intelligent polymers
MX356111B (es) Composiciones farmaceuticas disuasorias de abuso, de liberacion inmediata.
MX2010009043A (es) Composicion farmaceutica para farmacos poco solubles.
IN2012DN00570A (es)
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
EA200900572A1 (ru) Мицеллярные наночастицы с химическими субстанциями
WO2009025926A3 (en) Nanoparticle-coated medical devices and formulations for treating vascular disease
WO2010021607A3 (en) Pharmaceutical formulation
HK1208353A1 (en) Solid dosage form
CY1118461T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν αναστολεα αρωματασης
WO2011080141A3 (en) Degradable removable implant for the sustained release of an active compound
AR079804A1 (es) Composiciones cosmeticas de perlas en polvo
UY31452A1 (es) Recubrimiento mejorado de tableta
WO2013013038A3 (en) Doping agents and polymeric compositions thereof for controlled drug delivery
BRPI0920683A2 (pt) Composto, composição de composto ativo, semente, medicamento, e, métodos para controlar fungos fitopatogênicos, e para preparar um agente antimicótico
WO2012106016A3 (en) Oral care compositions
CL2009000452A1 (es) Tableta desintegrante oral que comprende cilostazol, particulas granuladas que se preparan por dispersion uniforme de una sustancia organica, un agente desintegrante en particulas que comprenden dos o mas sacaridos, un deslizante, un excipiente organico y opcionalmente un aditivo; y metodo para preparar esta tableta.
ECSP034915A (es) Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion
MX2010004291A (es) Producto de dispersion solida de farmacos basados en n-aril urea.